All bisphosphonates are (or May Not Be) the same: Potential reasons for clinical differences

Journal of Women's Health

Volumn 19, Issue 4, 2010, Pages 665-669

  Miller, Paul D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE REMODELING; BONE STRENGTH; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RISK REDUCTION; VERTEBRA FRACTURE; WRIST FRACTURE;

BIOMARKERS, PHARMACOLOGICAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; PROCESS ASSESSMENT (HEALTH CARE);

EID: 77951848226     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2010.1945     Document Type: Editorial

References (34)

1. Russell RG, Muhlbauer RCS, Bisaz D, et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapetite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res 1970;6: 183-189.
2. Russell RGG, Rogers M. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999;25:97-106.
3. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
4. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapetite. Bone 2006;38:617-627.
5. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759.
6. Miller PD. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ, eds. Osteoporosis, 3rd ed. San Diego, CA: Elsevier Academic Press, 2007:1725-1736.
7. Wasnich RD, Miller PD. Antifracture efficacy of antiresportive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:1-6.
8. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002;17:1139-1147.
9. Borah B, Dufresne TE, Ritman TL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone 2006;39: 345-352.
10. Bauss F, Dempster DW. Effects of ibandronate on bone quality: Preclinical studies. Bone 2007;40:265-273.
11. Bilezikian JP, Matsumoto T, Bellido T, et al. Targeting bone remodeling for the treatment of osteoporosis: Summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2009;24:373-385.
12. Bonnick SL, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-2637.
13. Miller PD, Epstein S, Sedarati F, Reginster JY. Once monthly oral ibandronate compared with weekly alendronate: Results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-213.
14. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20:2097-2104.
15. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of antifracture efficacy? Bone 2007;41: 308-317.
16. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003;33:150-158.
17. Cremers S, Bilezikian JP, Garnero P. Bone markers-New aspects. Clin Lab 2008;54:461-471.
18. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056.
19. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008;42:832-836.
20. Baim SR, Miller PD. The role of serum C-telopeptide (CTX) in the management of postmenopausal osteoporosis and its use in predicting osteonecrosis of the jaw (ONJ). J Bone Miner Res 2009;24:561-574.
21. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005;21:545-554.
22. Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep 2007;5:38-43.
23. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am J Med 2006;119(Suppl 1):S25-31.
24. Black DM, Delmas PD, Eastell R, et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
25. McClung MR, Geusens P, Miller PD, et al. The effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344: 333-340.
26. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1998;348:1535-1541.
27. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
28. Harris ST, Blumenthals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a metaanalysis of phase III studies. Curr Med Res Opin 2008;24: 237-245.
29. Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: Challenges with interpreting clinical trial data. Curr Med Res Opin 2008;24:107-119.
30. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-1298.
31. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007;357:1799-1809.
32. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74:641-648.
33. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Safety 2007;6:663-672.
34. Miller PD. Fragility fractures in chronic kidney disease: An opinion-based approach. Cleve Clin J Med 2009;76:715-723.